Paramount Shouldn't Fold to Trump
Almost immediately, the Federal Communications Commission (FCC) was investigating CBS for what became known as "Nipplegate." The network then turned to my boss, who enlisted my help, to defend against indecency charges. Years of opposition before the agency and in appeals court followed. During that time, the FCC also proposed to fine CBS even more for an episode of Without A Trace with a scene depicting a teenage hook-up party, which the commission claimed was impermissible under its indecency standards.
Eventually, the network prevailed in court, and the FCC had to cut CBS a check returning the fines it had paid for the halftime show. (The Without a Trace matter ultimately got dropped.)
Now CBS is back in the news. Less than two weeks into President Donald Trump's second term, the network's parent company Paramount is considering settling his lawsuit claiming CBS' coverage of the presidential campaign—and, in particular, an allegedly deceptively edited interview with Kamala Harris—was unfair and somehow harmed him. Reports have tied this possible settlement to Paramount's planned merger with Skydance, which Paramount shareholders fear the new administration could try to block or delay.
Notably, this also comes against a backdrop of President Trump's appointed FCC Chairman Brendan Carr rattling his saber at broadcast networks that have earned the president's ire.
Shortly before the inauguration, under the guidance of its former, Joe Biden–appointed chair, the FCC dismissed complaints against ABC, CBS, Fox, and NBC regarding broadcasts during the campaign—including CBS' 60 Minutes Harris interview. In doing so, the FCC emphasized the importance of honoring CBS' editorial discretion and broadcasters' First Amendment right to report on matters of public concern as they see fit. But Trump's handpicked successor has indicated the FCC will reconsider that dismissal, along with the NBC and ABC dismissals (but not the Fox dismissal, unsurprisingly).
Freedom of the press protects journalists and the news media in publishing information—especially in the political sphere—free from official censorship. In that way, a free press serves a vital role as the "Fourth Estate" in our democratic society, keeping citizens informed so that individuals may oversee their government's actions. As Ida B. Wells stated, "The people must know before they can act, and there is no educator to compare with the press."
That's why it's concerning that CBS would go to the mattresses over a halftime show for a game it gets once every fourth year, or even a bread-and-butter scripted show like Without a Trace, but would capitulate when it comes to its news and political coverage. Already the network is reportedly poised to comply with an FCC demand for the transcript and camera feeds from the 60 Minutes interview.
When parties to legal disputes resolve them with monetary payments rather than seeing them through to a decision, it is often said they are "buying peace." Here, there is no peace to be bought, at least not without reassurance from the courts that CBS can cover political matters as its editorial discretion dictates, no matter how much it might displease the president or his appointees.
Let's be clear: Paramount isn't buying peace—it's only buying CBS a four-year supply of lube.
The post Paramount Shouldn't Fold to Trump appeared first on Reason.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Why Investors Were So Fired Up About First Solar Stock on Friday
Key Points Data center operators are unhappy with potential changes to federal incentives for green energy solutions. A group of them are lobbying the Trump administration to leave these incentives alone for now. 10 stocks we like better than First Solar › The solar industry has struggled mightily for years to achieve meaningful growth and post net profits. During the Biden administration, the green energy sector as a whole received something of a break in the 2022 Inflation Reduction Act, with a slew of tax incentives for building out alternative-energy solutions. In its attempt to reverse this, President Donald Trump has tasked his administration to make the current subsidies harder to obtain. Thankfully for green energy companies, a theoretically influential lobbying group stepped in on Friday to push back against this effort. Numerous solar stocks popped on the news, including First Solar (NASDAQ: FSLR), which rose a sturdy 11% by market close. A mighty lob by a lobbying group The business grouping behind Friday's pushback is the Data Center Coalition. News broke that the coalition sent a formal request to Treasury Secretary Scott Bessent to maintain the subsidy policy as it is, rather than changing it. The organization -- which lists as members Amazon, Oracle, and CoreWeave, among other prominent tech companies -- told Bessent that any regulatory roadblock limiting green energy solutions will hamper the development of artificial intelligence (AI). Many data center operators are currently building out their facilities to handle the vastly increased resource demands of AI. To do so, they require more energy, hence their support of renewable sources like solar. Does the silence speak volumes? Bessent hasn't yet publicly responded to the coalition's lobbying effort, nor has anyone else in the Trump administration. But investors seem convinced that they've not only digested the letter, they're taking it seriously, since the organization behind it has many prominent members who drive the U.S. economy. Should you invest $1,000 in First Solar right now? Before you buy stock in First Solar, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and First Solar wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, First Solar, and Oracle. The Motley Fool has a disclosure policy. Why Investors Were So Fired Up About First Solar Stock on Friday was originally published by The Motley Fool
New York Times
an hour ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
New York Post
an hour ago
- New York Post
Ukrainian sniper breaks world record with 13,000-foot kill shot against Russian forces: report
A Ukrainian sniper unit on Thursday reportedly broke the world record for the longest confirmed sniper kill, eliminating Russian troops from a distance of more than 13,000 feet. The shot, fired by a Ukrainian-produced rifle and aided by artificial intelligence and drone guidance, left two Russian soldiers dead in the area of Pokrovsk, Ukraine, the Kyiv Post reported. 'The record-breaking shot was made on Aug. 14, 2025, using artificial intelligence under the guidance of [an unmanned aerial vehicle] complex with a 14.5 mm alligator rifle,' said military journalist Yuri Butusov, according to the Kyiv Post. The shooting took place amid increased Russian attacks in the area surrounding Pokrovsk, which was once a city with more than 60,000 residents, the Post reported. The previous world record belonged to a 58-year-old Ukrainian sniper who eliminated a target from a distance of around 12,400 feet, the outlet added. The record-breaking shot reportedly took place a day before President Donald Trump's closely-watched summit Friday with Russian President Vladimir Putin. 3 A Ukrainian soldier in the sniper unit of the 108th Territorial Defense Brigade readies a rifle during training on Nov. 4, 2023. Anadolu via Getty Images 3 The previous world record was held by another Ukrainian sniper who took out a Russian soldier from nearly 2½ miles away with a high-tech rifle known as 'Horizon's Lord.' SBU 3 Ukrainian soldiers take part in a sniper shooting exercise at a training facility outside Kyiv on Nov. 21, 2023. AFP via Getty Images Putin, who spoke first in a joint press conference held by the two world leaders, described the talks as a 'constructive atmosphere of mutual respect.' Ukrainian President Volodymyr Zelensky is scheduled to meet with Trump in Washington, DC, Monday. Zelensky said in a post on X that he and Trump will 'discuss all of the details regarding ending the killing and the war.'
